Deep Bio: An artificial intelligence-based prostate cancer diagnosis aid developed by a Korean company has received marketing authorization from overseas regulators, attracting the industry’s attention. Deep Bio said Tuesday that its...

Deep Bio: An award ceremony was held on July 4th, where Director Byeonggweon Lee from the Korean Ministry of SMEs and Startups (MSS) presented a plaque and expressed confidence in Deep Bio’s potential. SEOUL, SOUTH KOREA (PRWEB) JULY 07,...

Seasoned Industry Expert Joins Deep Bio to Drive Commercial Growth and Expansion. Deep Bio appoints Grant Carlson as the company’s Chief Commercial Officer. SEOUL, SOUTH KOREA (PRWEB) JULY 30, 2023 Deep Bio, a leader in artificial...

Deep Bio, a leading AI biotech dedicated to cancer diagnosis, and Visiopharm, a world leader in AI-powered image analysis and tissue mining for research and diagnostics, announced a strategic partnership to provide pathologists access to the...

Deep Bio: Enhanced security and reliability through adherence to the globally recognized information security standards SEOUL, SOUTH KOREA (PRWEB) OCTOBER 27, 2022 Deep Bio, a pioneer in medical AI for digital pathology and cancer...

Deep Bio said it signed a partnership with Visiopharm, a Danish pharmaceutical company, to supply DeepDx Prostate, its deep learning-based prostate cancer pathology image analysis software. Under the agreement, Deep Bio will be able to...